Last reviewed · How we verify
NCT07363369
Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
Phase 1 trial testing FAP mRNA vaccine (dose 1) + immune checkpoint inhibitors in Advanced Malignant Solid Tumors in 10 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | West China Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 25 January 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- FAP mRNA vaccine (dose 1) + immune checkpoint inhibitors — full drug profile →
- FAP mRNA vaccine (dose 2) + immune checkpoint inhibitors
- FAP mRNA vaccine (dose 3) + immune checkpoint inhibitors
- FAP mRNA vaccine (dose 4) + immune checkpoint inhibitors
Conditions studied
- Advanced Malignant Solid Tumors — all drugs for Advanced Malignant Solid Tumors →
Sponsor
West China Hospital
Who can join
18 and older, any sex, with Advanced Malignant Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cancer-associated fibroblasts (CAFs), as core regulators within the tumor microenvironment, significantly impede the intratumoral penetration of therapeutic agents and suppress the effective infiltration and activation of immune cells by constructing elaborate physical and functional barriers. Fibroblast activation protein (FAP) is a highly specific therapeutic target for CAFs, owing to its nearly tumor-restricted expression profile. Therefore, developing therapeutic strategies that specifically target FAP to eliminate CAFs and subsequently remodel the tumor microenvironment may effectively disrupt the multi-dimensional defense system established by CAFs, thereby significantly enhancing the delivery efficiency of anti-tumor agents and improving responsiveness to immunotherapy. This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of FAP mRNA Vaccine combined with immune checkpoint inhibitors in patients with advanced malignant solid tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07363369
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Malignant Solid Tumors
Currently open trials in the same condition.
- NCT07292402 — JSKN022 in Subjects With Advanced Malignant Solid Tumors · Phase 1 · recruiting
- NCT06717750 — A Study of CSCJC3456 in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT06728189 — A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors · Phase 1 · recruiting
- NCT06499350 — A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT06571422 — Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors · Phase 1 · recruiting
Other West China Hospital trials
Trials by the same sponsor.
- NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
- NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07363369 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West China Hospital
- Last refreshed: 23 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07363369.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing